Kevin D. Cook
Kevin D. Cook has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
Marcus Soto
Pharmacokinetics & Drug Metabolism, Amgen Research, One Amgen Center Drive, Thousand Oaks, CA, 91320, USA
3 shared publicationsCarrie Poon-Andersen
Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 750 Gateway Blvd, Suite 100, South San Francisco, CA, 94080
2 shared publications- Chi-Ming Li
Amgen Inc
2 shared publications - Devin L. Wakefield
Amgen, South San Francisco, CA, USA
2 shared publications Diana Wong
Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 750 Gateway Blvd, Suite 100, South San Francisco, CA, 94080
2 shared publications- Kip P. Conner
Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 750 Gateway Blvd, Suite 100, South San Francisco, CA, 94080
2 shared publications
Latest Publications
- Open Access
- 7 April 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (3) , 87
Predicting Aberrant Fc-fusion Protein Pharmacokinetics from In Silico Structural Properties and Physiologically Based Pharmacokinetic (PBPK) Modeling
The fusion of therapeutic proteins to the Fc domain of monoclonal antibodies (mAbs) generally improves the proteins' pharmacokinetic (PK) characteristics, extending in vivo half-lives due to the binding of the Fc domain to the FcRn receptor. Yet, several of these Fc-fusion biologics have been observed to have unexpected rapid clearance associated with non-specific off-target binding. Variability in non-specific clearance is often challenging to predict, not well understood, and ultimately can delay the drug development process. In this investigation, we present a computational approach leveraging in silico protein structural properties to extend a physiologically based pharmacokinetic (PBPK) model of mAbs validated on in vivo plasma PK profiles in mice. Selected model parameters affecting protein half-life have been scaled by analytical functions of a panel of calculated in silico protein properties identified by a novel and ad hoc symbolic regression procedure. The resulting extended model has been successfully validated against an independent set of protein plasma PKs, indicating that it can generalize to novel biologics of the same class. Moreover, the extended PBPK model has a median absolute average fold error (AAFE) of 1.18 (min = 1.09; max = 1.51), where values less than 2 typically indicate a good fit. The results enable the de-risking of aberrant PK behaviors, ultimately leading to the selection of Fc-fusion proteins with increased therapeutic value for patients.
- 7 April 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (3) , 87
Open AccessPredicting Aberrant Fc-fusion Protein Pharmacokinetics from In Silico Structural Properties and Physiologically Based Pharmacokinetic (PBPK) Modeling
The fusion of therapeutic proteins to the Fc domain of monoclonal antibodies (mAbs) generally improves the proteins' pharmacokinetic (PK) characteristics, extending in vivo half-lives due to the binding of the Fc domain to the FcRn receptor. Yet, several of these Fc-fusion biologics have been observed to have unexpected rapid clearance associated with non-specific off-target binding. Variability in non-specific clearance is often challenging to predict, not well understood, and ultimately can delay the drug development process. In this investigation, we present a computational approach leveraging in silico protein structural properties to extend a physiologically based pharmacokinetic (PBPK) model of mAbs validated on in vivo plasma PK profiles in mice. Selected model parameters affecting protein half-life have been scaled by analytical functions of a panel of calculated in silico protein properties identified by a novel and ad hoc symbolic regression procedure. The resulting extended model has been successfully validated against an independent set of protein plasma PKs, indicating that it can generalize to novel biologics of the same class. Moreover, the extended PBPK model has a median absolute average fold error (AAFE) of 1.18 (min = 1.09; max = 1.51), where values less than 2 typically indicate a good fit. The results enable the de-risking of aberrant PK behaviors, ultimately leading to the selection of Fc-fusion proteins with increased therapeutic value for patients.
- Top Cited Papers
- 2 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6793) , eadx1736
Targeting modulated vascular smooth muscle cells in atherosclerosis via FAP-directed immunotherapy
Vascular smooth muscle cell (VSMC) diversification drives atherosclerotic coronary artery disease (CAD), but the mechanisms governing these cell state transitions remain unclear. We applied multiomic single-cell profiling, epitope mapping, and spatial transcriptomics across 27 human coronary arteries, identifying fibroblast activation protein (FAP) as a marker of modulated VSMCs. Lineage tracing in mice indicated that FAP + cells originate from Myh11 + VSMCs, and FAP positron emission tomography imaging in CAD patients showed plaque uptake. FAP + cell states resided in the macrophage-rich neo-intima. Therapeutically, we developed an anti-FAP bispecific T cell engager, which reduced plaque burden and remodeled the stromal–immune microenvironment through T cell clonal expansion. Our study delivers a single-cell and spatial atlas of human CAD, establishes FAP as a marker of modulated VSMCs, and highlights immunotherapy for lipid-independent targets.
- 2 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6793) , eadx1736
Top Cited PapersTargeting modulated vascular smooth muscle cells in atherosclerosis via FAP-directed immunotherapy
Vascular smooth muscle cell (VSMC) diversification drives atherosclerotic coronary artery disease (CAD), but the mechanisms governing these cell state transitions remain unclear. We applied multiomic single-cell profiling, epitope mapping, and spatial transcriptomics across 27 human coronary arteries, identifying fibroblast activation protein (FAP) as a marker of modulated VSMCs. Lineage tracing in mice indicated that FAP + cells originate from Myh11 + VSMCs, and FAP positron emission tomography imaging in CAD patients showed plaque uptake. FAP + cell states resided in the macrophage-rich neo-intima. Therapeutically, we developed an anti-FAP bispecific T cell engager, which reduced plaque burden and remodeled the stromal–immune microenvironment through T cell clonal expansion. Our study delivers a single-cell and spatial atlas of human CAD, establishes FAP as a marker of modulated VSMCs, and highlights immunotherapy for lipid-independent targets.
- Open Access
- 29 April 2025
- Published by Springer Nature in Nature Metabolism
- Vol. 7 (6) , 1266-1281
GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice
Glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide 1 receptor (GLP-1R) are expressed in the central nervous system (CNS) and regulate food intake. Here, we demonstrate that a peptide–antibody conjugate that blocks GIPR while simultaneously activating GLP-1R (GIPR-Ab/GLP-1) requires both CNS GIPR and CNS GLP-1R for maximal weight loss in obese, primarily male, mice. Moreover, dulaglutide produces greater weight loss in CNS GIPR knockout (KO) mice, and the weight loss achieved with dulaglutide + GIPR-Ab is attenuated in CNS GIPR KO mice. Wild-type mice treated with GIPR-Ab/GLP-1 and CNS GIPR KO mice exhibit similar changes in gene expression related to tissue remodelling, lipid metabolism and inflammation in white adipose tissue and liver. Moreover, GIPR-Ab/GLP-1 is detected in circumventricular organs in the brain and activates c-FOS in downstream neural substrates involved in appetite regulation. Hence, both CNS GIPR and GLP-1R signalling are required for the full weight loss effect of a GIPR-Ab/GLP-1 peptide–antibody conjugate.
- 29 April 2025
- Published by Springer Nature in Nature Metabolism
- Vol. 7 (6) , 1266-1281
Open AccessGIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice
Glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide 1 receptor (GLP-1R) are expressed in the central nervous system (CNS) and regulate food intake. Here, we demonstrate that a peptide–antibody conjugate that blocks GIPR while simultaneously activating GLP-1R (GIPR-Ab/GLP-1) requires both CNS GIPR and CNS GLP-1R for maximal weight loss in obese, primarily male, mice. Moreover, dulaglutide produces greater weight loss in CNS GIPR knockout (KO) mice, and the weight loss achieved with dulaglutide + GIPR-Ab is attenuated in CNS GIPR KO mice. Wild-type mice treated with GIPR-Ab/GLP-1 and CNS GIPR KO mice exhibit similar changes in gene expression related to tissue remodelling, lipid metabolism and inflammation in white adipose tissue and liver. Moreover, GIPR-Ab/GLP-1 is detected in circumventricular organs in the brain and activates c-FOS in downstream neural substrates involved in appetite regulation. Hence, both CNS GIPR and GLP-1R signalling are required for the full weight loss effect of a GIPR-Ab/GLP-1 peptide–antibody conjugate.
- 14 July 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (10) , 3100-3111
Utility of Cellular Measurements of Non-Specific Endocytosis to Assess the Target-Independent Clearance of Monoclonal Antibodies
- 14 July 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (10) , 3100-3111
Utility of Cellular Measurements of Non-Specific Endocytosis to Assess the Target-Independent Clearance of Monoclonal Antibodies
- Open Access
- 19 June 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (9) , 2879-2894
Cellular Neonatal Fc Receptor Recycling Efficiencies can Differentiate Target-Independent Clearance Mechanisms of Monoclonal Antibodies
- 19 June 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (9) , 2879-2894
Open AccessCellular Neonatal Fc Receptor Recycling Efficiencies can Differentiate Target-Independent Clearance Mechanisms of Monoclonal Antibodies
- 22 December 2023
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 52 (3) , 228-235
Correlation of In Vitro Kinetic Stability to Preclinical In Vivo Pharmacokinetics for a Panel of Anti-PD-1 Monoclonal Antibody Interleukin 21 Mutein Immunocytokines
The development of therapeutic fusion protein drugs is often impeded by the unintended consequences that occur from fusing together domains from independent naturally occurring proteins, consequences such as altered biodistribution, tissue uptake or rapid clearance and potential immunogenicity. For therapeutic fusion proteins containing globular domains, we hypothesized that aberrant in vivo behavior could be related to low kinetic stability of these domains leading to local unfolding and susceptibility to partial proteolysis and/or salvage and uptake. Herein we describe an assay to measure kinetic stability of therapeutic fusion proteins by way of their sensitivity to the protease thermolysin. The results indicate that in vivo pharmacokinetics of a panel of anti-PD-1 monocolonal antibody:IL-21 immunocytokines in both mice and non-human primates are highly correlated with their in vitro susceptibility to thermolysin-mediated proteolysis. This assay can be used as a tool to quickly identify in vivo liabilities of globular domains of therapeutic proteins, thus aiding in the optimization and development of new multi-specific drug candidates. Significance Statement This work describes a novel assay utilizing protein kinetic stability to identify in vivo pharmacokinetic liabilities of multi-specific therapeutic fusion proteins. This provides an efficient, inexpensive method to ascertain inherent protein stability in vitro before conducting in vivo studies, which can rapidly increase the speed of pre-clinical drug development.
- 22 December 2023
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 52 (3) , 228-235
Correlation of In Vitro Kinetic Stability to Preclinical In Vivo Pharmacokinetics for a Panel of Anti-PD-1 Monoclonal Antibody Interleukin 21 Mutein Immunocytokines
The development of therapeutic fusion protein drugs is often impeded by the unintended consequences that occur from fusing together domains from independent naturally occurring proteins, consequences such as altered biodistribution, tissue uptake or rapid clearance and potential immunogenicity. For therapeutic fusion proteins containing globular domains, we hypothesized that aberrant in vivo behavior could be related to low kinetic stability of these domains leading to local unfolding and susceptibility to partial proteolysis and/or salvage and uptake. Herein we describe an assay to measure kinetic stability of therapeutic fusion proteins by way of their sensitivity to the protease thermolysin. The results indicate that in vivo pharmacokinetics of a panel of anti-PD-1 monocolonal antibody:IL-21 immunocytokines in both mice and non-human primates are highly correlated with their in vitro susceptibility to thermolysin-mediated proteolysis. This assay can be used as a tool to quickly identify in vivo liabilities of globular domains of therapeutic proteins, thus aiding in the optimization and development of new multi-specific drug candidates. Significance Statement This work describes a novel assay utilizing protein kinetic stability to identify in vivo pharmacokinetic liabilities of multi-specific therapeutic fusion proteins. This provides an efficient, inexpensive method to ascertain inherent protein stability in vitro before conducting in vivo studies, which can rapidly increase the speed of pre-clinical drug development.
- 12 May 2022
- Published by Taylor & Francis in Bioanalysis
- Vol. 14 (9) , 581-588
Development of an Immunoassay for Aglycosylated Murine IgG1 in Mouse Serum via Generation of a Specific Tool Antibody
Aim: To develop a method for the quantitation of effector functionless mouse surrogate IgG1 drug molecules in mouse matrices. Materials & methods: A panel of antibodies that bound specifically to N...
- 12 May 2022
- Published by Taylor & Francis in Bioanalysis
- Vol. 14 (9) , 581-588
Development of an Immunoassay for Aglycosylated Murine IgG1 in Mouse Serum via Generation of a Specific Tool Antibody
Aim: To develop a method for the quantitation of effector functionless mouse surrogate IgG1 drug molecules in mouse matrices. Materials & methods: A panel of antibodies that bound specifically to N...
- 25 August 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (608)
Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors
Immune checkpoint blockade and 4-1BB agonism overcome primary resistance to bispecific T cell engager therapy in T cell–cold solid tumors.
- 25 August 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (608)
Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors
Immune checkpoint blockade and 4-1BB agonism overcome primary resistance to bispecific T cell engager therapy in T cell–cold solid tumors.
- Open Access
Regulatory T cell expansion by a highly CD25-dependent IL-2 mutein arrests ongoing autoimmunity
Interleukin-2 (IL-2) controls the homeostasis and function of regulatory T cells (Tregs) and defects in the IL-2 pathway contribute to multiple autoimmune diseases. Although recombinant IL-2 therapy has been efficacious in certain inflammatory conditions, the capacity for IL-2 to also activate inflammatory effector responses highlights the need for IL-2-based therapeutics with improved Treg-specificity. From a panel of rationally designed IL-2 variants, we identified IL-2 muteins with reduced potency and enhanced Treg-selectivity due to increased dependence on the IL-2-receptor component CD25. As an Fc-fused homodimer, the optimal Fc.IL-2 mutein induced selective Treg enrichment and reduced agonism of effector cells across a wide dose range. Furthermore, despite being a weaker agonist, overall Treg growth was greater and more sustained due to reduced receptor-mediated clearance of the Fc.IL-2 mutein compared to Fc-fused wild-type IL-2. Preferential Treg enrichment was also observed in the presence of activated pathogenic T cells in the autoimmune target organ, despite a loss of Treg-selectivity in an IL-2R-proximal response. These features allowed for extended resolution of spontaneous autoimmunity using infrequent dosing schedules. Thus, IL-2 muteins enable efficient, flexible, and targeted control of the autoimmune response. One Sentence Summary: A CD25-dependent IL-2 mutein selectively expands regulatory T cells and provides potent and targeted control of autoimmunity.
Open AccessRegulatory T cell expansion by a highly CD25-dependent IL-2 mutein arrests ongoing autoimmunity
Interleukin-2 (IL-2) controls the homeostasis and function of regulatory T cells (Tregs) and defects in the IL-2 pathway contribute to multiple autoimmune diseases. Although recombinant IL-2 therapy has been efficacious in certain inflammatory conditions, the capacity for IL-2 to also activate inflammatory effector responses highlights the need for IL-2-based therapeutics with improved Treg-specificity. From a panel of rationally designed IL-2 variants, we identified IL-2 muteins with reduced potency and enhanced Treg-selectivity due to increased dependence on the IL-2-receptor component CD25. As an Fc-fused homodimer, the optimal Fc.IL-2 mutein induced selective Treg enrichment and reduced agonism of effector cells across a wide dose range. Furthermore, despite being a weaker agonist, overall Treg growth was greater and more sustained due to reduced receptor-mediated clearance of the Fc.IL-2 mutein compared to Fc-fused wild-type IL-2. Preferential Treg enrichment was also observed in the presence of activated pathogenic T cells in the autoimmune target organ, despite a loss of Treg-selectivity in an IL-2R-proximal response. These features allowed for extended resolution of spontaneous autoimmunity using infrequent dosing schedules. Thus, IL-2 muteins enable efficient, flexible, and targeted control of the autoimmune response. One Sentence Summary: A CD25-dependent IL-2 mutein selectively expands regulatory T cells and provides potent and targeted control of autoimmunity.
- 1 July 2019
- Published by Elsevier in Journal of Immunological Methods
- Vol. 470, 55-58
A quantitative method for detection of circulating fms related tyrosine kinase 3 (FLT-3) in acute myeloid leukemia (AML) patients
- 1 July 2019
- Published by Elsevier in Journal of Immunological Methods
- Vol. 470, 55-58
A quantitative method for detection of circulating fms related tyrosine kinase 3 (FLT-3) in acute myeloid leukemia (AML) patients